Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001969474 | SCV002261758 | uncertain significance | Fanconi anemia | 2022-04-09 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with SLX4-related conditions. This variant is present in population databases (rs756660911, gnomAD 0.01%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1445 of the SLX4 protein (p.Arg1445Gln). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. |
Fulgent Genetics, |
RCV002497927 | SCV002806227 | uncertain significance | Fanconi anemia complementation group P | 2021-12-16 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004671580 | SCV005167132 | uncertain significance | Inborn genetic diseases | 2024-06-19 | criteria provided, single submitter | clinical testing | The c.4334G>A (p.R1445Q) alteration is located in exon 12 (coding exon 11) of the SLX4 gene. This alteration results from a G to A substitution at nucleotide position 4334, causing the arginine (R) at amino acid position 1445 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |